James Mann

2.1k total citations
56 papers, 1.5k citations indexed

About

James Mann is a scholar working on Pharmaceutical Science, Materials Chemistry and Molecular Biology. According to data from OpenAlex, James Mann has authored 56 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Pharmaceutical Science, 19 papers in Materials Chemistry and 11 papers in Molecular Biology. Recurrent topics in James Mann's work include Drug Solubulity and Delivery Systems (37 papers), Crystallization and Solubility Studies (19 papers) and Protein purification and stability (9 papers). James Mann is often cited by papers focused on Drug Solubulity and Delivery Systems (37 papers), Crystallization and Solubility Studies (19 papers) and Protein purification and stability (9 papers). James Mann collaborates with scholars based in United Kingdom, Belgium and United States. James Mann's co-authors include Talia Flanagan, Samuel R. Pygall, Nikoletta Fotaki, Daniel J. Phillips, E. J. Meehan, Jennifer Dressman, Giuseppina Mandalari, Richard M. Faulks, Patrick Augustijns and James Butler and has published in prestigious journals such as Blood, International Journal of Pharmaceutics and Journal of Pharmaceutical Sciences.

In The Last Decade

James Mann

53 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
James Mann United Kingdom 19 858 341 230 215 186 56 1.5k
Deanna M. Mudie United States 15 995 1.2× 330 1.0× 216 0.9× 201 0.9× 106 0.6× 20 1.5k
Grzegorz Garbacz Poland 19 1.0k 1.2× 297 0.9× 210 0.9× 212 1.0× 160 0.9× 66 1.6k
Uwe Muenster Germany 14 650 0.8× 226 0.7× 157 0.7× 130 0.6× 138 0.7× 23 1.2k
Nikoletta Fotaki United Kingdom 22 1.2k 1.4× 434 1.3× 277 1.2× 253 1.2× 436 2.3× 115 2.0k
Konstantinos Goumas Greece 16 841 1.0× 288 0.8× 199 0.9× 134 0.6× 134 0.7× 29 1.5k
Talia Flanagan United Kingdom 18 550 0.6× 197 0.6× 181 0.8× 126 0.6× 282 1.5× 42 1.1k
John Hempenstall United Kingdom 15 1.0k 1.2× 525 1.5× 191 0.8× 313 1.5× 161 0.9× 25 1.6k
Ekarat Jantratid Germany 17 1.3k 1.5× 478 1.4× 230 1.0× 376 1.7× 149 0.8× 23 1.6k
Jelena Parojčić Serbia 22 657 0.8× 194 0.6× 128 0.6× 230 1.1× 100 0.5× 70 1.2k
Mirko Koziolek Germany 25 1.3k 1.5× 247 0.7× 328 1.4× 205 1.0× 208 1.1× 59 2.2k

Countries citing papers authored by James Mann

Since Specialization
Citations

This map shows the geographic impact of James Mann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Mann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Mann more than expected).

Fields of papers citing papers by James Mann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Mann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Mann. The network helps show where James Mann may publish in the future.

Co-authorship network of co-authors of James Mann

This figure shows the co-authorship network connecting the top 25 collaborators of James Mann. A scholar is included among the top collaborators of James Mann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Mann. James Mann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Mann, James, et al.. (2025). Linking powder to tablet stability: Length- and time-scale prediction of moisture sorption. International Journal of Pharmaceutics. 684. 126154–126154.
3.
Anderson, Andrew E., Håkan Wikström, Melanie Dumarey, et al.. (2025). Comparative analysis of tablet dissolution behavior: Batch vs. Continuous direct compression. International Journal of Pharmaceutics. 675. 125498–125498. 1 indexed citations
4.
Carroll, Mark, James Mann, Adrian Davis, et al.. (2025). Particle-based investigation of excipients stability: the effect of storage conditions on moisture content and swelling. 2(2). 369–386. 2 indexed citations
5.
Engman, Helena, Sara Carlert, Richard A. Barker, et al.. (2025). Leveraging Biopharmaceutics Bridging Risk Assessment and In Vivo Predictive Tools to Accelerate Immediate Release Drug Product Development by Minimized Need for Clinical Bridging Studies. Molecular Pharmaceutics. 22(10). 6203–6214. 1 indexed citations
6.
Armstrong, John A., et al.. (2024). Flexible modelling of the dissolution performance of directly compressed tablets. International Journal of Pharmaceutics. 656. 124084–124084. 9 indexed citations
7.
Sharma, Shringi, Xavier Pépin, Jean Cheung, et al.. (2022). Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjects. British Journal of Clinical Pharmacology. 88(10). 4573–4584. 3 indexed citations
8.
Khadra, Ibrahim, et al.. (2022). Formulation-dependent stability mechanisms affecting dissolution performance of directly compressed griseofulvin tablets. International Journal of Pharmaceutics. 631. 122473–122473. 11 indexed citations
9.
Sharma, Shringi, Xavier Pépin, Haran Burri, et al.. (2021). New Acalabrutinib Formulation Enables Co-Administration with Proton Pump Inhibitors and Dosing in Patients Unable to Swallow Capsules (ELEVATE-PLUS). Blood. 138(Supplement 1). 4365–4365. 8 indexed citations
10.
Αbeele, Jens Van Den, Richard A. Barker, James Mann, et al.. (2020). The effect of reduced gastric acid secretion on the gastrointestinal disposition of a ritonavir amorphous solid dispersion in fasted healthy volunteers: an in vivo - in vitro investigation.. European Journal of Pharmaceutical Sciences. 151. 105377–105377. 20 indexed citations
11.
Mann, James, et al.. (2020). Prediction of plasma profiles of a weakly basic drug after administration of omeprazole using PBPK modeling. European Journal of Pharmaceutical Sciences. 158. 105656–105656. 7 indexed citations
12.
Flanagan, Talia, et al.. (2020). Impact of Magnesium Stearate Presence and Variability on Drug Apparent Solubility Based on Drug Physicochemical Properties. The AAPS Journal. 22(4). 75–75. 18 indexed citations
13.
14.
Flanagan, Talia, et al.. (2020). Surface dissolution UV imaging for characterization of superdisintegrants and their impact on drug dissolution. International Journal of Pharmaceutics. 577. 119080–119080. 13 indexed citations
15.
16.
Pépin, Xavier, et al.. (2019). Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part I. Mechanistic modelling of drug product dissolution to derive a P-PSD for PBPK model input. European Journal of Pharmaceutics and Biopharmaceutics. 142. 421–434. 38 indexed citations
17.
Mann, James, Jennifer Dressman, Karin M. Rosenblatt, et al.. (2017). Validation of Dissolution Testing with Biorelevant Media: An OrBiTo Study. Molecular Pharmaceutics. 14(12). 4192–4201. 75 indexed citations
18.
Kostewicz, Edmund, Bertil Abrahamsson, Marcus E. Brewster, et al.. (2013). In vitro models for the prediction of in vivo performance of oral dosage forms. European Journal of Pharmaceutical Sciences. 57. 342–366. 299 indexed citations
19.
Mann, James & Samuel R. Pygall. (2012). A Formulation Case Study Comparing the Dynamic Gastric Model with Conventional Dissolution Methods. Dissolution Technologies. 19(4). 14–19. 21 indexed citations
20.
Dieterle, W., et al.. (2005). Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. International Journal of Clinical Pharmacology and Therapeutics. 43(11). 527–535. 71 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Deanna M. Mudie Breakdown of academic impact, for papers by Grzegorz Garbacz Breakdown of academic impact, for papers by Uwe Muenster Breakdown of academic impact, for papers by Nikoletta Fotaki Breakdown of academic impact, for papers by Konstantinos Goumas Breakdown of academic impact, for papers by Talia Flanagan Breakdown of academic impact, for papers by John Hempenstall Breakdown of academic impact, for papers by Ekarat Jantratid Breakdown of academic impact, for papers by Jelena Parojčić Breakdown of academic impact, for papers by Mirko Koziolek
Rankless by CCL
2026